You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
|
|---|---|
| Published in |
Breast Cancer Research, October 2018
|
| DOI | 10.1186/s13058-018-1050-7 |
| Pubmed ID | |
| Authors |
Gabriel N. Hortobagyi |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 101 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 11% |
| Student > Master | 10 | 10% |
| Student > Bachelor | 9 | 9% |
| Other | 7 | 7% |
| Student > Ph. D. Student | 6 | 6% |
| Other | 23 | 23% |
| Unknown | 35 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 12% |
| Biochemistry, Genetics and Molecular Biology | 7 | 7% |
| Unspecified | 2 | 2% |
| Nursing and Health Professions | 2 | 2% |
| Other | 8 | 8% |
| Unknown | 40 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2022.
All research outputs
#3,562,978
of 25,385,509 outputs
Outputs from Breast Cancer Research
#403
of 2,054 outputs
Outputs of similar age
#70,355
of 360,563 outputs
Outputs of similar age from Breast Cancer Research
#19
of 40 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,563 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.